Health Care • Biotechnology: Pharmaceutical Preparations
$15.95 ▲ +0.22
(+1.40%)
MKT CAP: $786.5M • VOL: 658.3K
52W L $11 52W H $36
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$13
MEDIAN
$18
MEAN
$18
HIGH
$22
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AVBP TAPE
AVBP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $19.30 | $18.34 | 2025-02-14 | $14.51 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $20.10 | $18.82 | 2025-02-06 | $14.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $18.18 | $17.55 | 2025-01-29 | $15.31 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $16.27 | — | 2025-01-17 | $15.63 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $14.04 | $15.15 | 2025-01-09 | $14.20 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $18.98 | $16.59 | 2024-12-18 | $13.88 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $15.47 | $16.11 | 2024-12-04 | $14.83 | -4.3% | 48% | C |